CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas

Modern Pathology

Volumn 22, Issue 6, 2009, Pages 744-752

  Soares, Maria J ^a   Pinto, Mafalda ^a   Henrique, Rui ^a,b   Vieira, Joana ^a   Cerveira, Nuno ^a   Peixoto, Ana ^a   Martins, Ana T ^a   Oliveira, Jorge ^a   Jerónimo, Carmen ^a,b,c   Teixeira, Manuel R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

CSF1R oncogene; Mutation; Overexpression; Renal cell carcinoma

Indexed keywords

COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ANGIOMYOLIPOMA; ARTICLE; CANCER DIAGNOSIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CSF1R GENE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOME; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; NUMERICAL CHROMOSOME ABERRATION; ONCOCYTOMA; PAPILLARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; UROGENITAL TRACT CANCER;

EID: 67349179639     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.43     Document Type: Article

References (39)

1. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancerbase No. 5, version 2.0 edn. IARC Press: Lyon, 2004.
2. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-133.
3. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
4. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14: 4726-4734.
5. Yang ZQ, Yoshida MA, Fukuda Y, et al. Molecular cytogenetic analysis of 17 renal cancer cell lines: increased copy number at 5q31-33 in cell lines from nonpapillary carcinomas. Jpn J Cancer Res 2000;91: 156-163.
6. Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood) 2004;229:1-11.
7. Ridge SA, Worwood M, Oscier D, et al. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 1990;87:1377-1380.
8. McGlynn H, Baker AH, Padua RA. Biological consequences of a point mutation at codon 969 of the FMS gene. Leuk Res 1998;22:365-372.
9. Yang DH, Huang W, Cui J, et al. The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. Hepatobili-ary Pancreat Dis Int 2004;3:86-89.
10. Gu TL, Mercher T, Tyner JW, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 2007;110:323-333.
11. Strefford JC, Stasevich I, Lane TM, et al. A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma. Cancer Genet Cytogenet 2005;159:1-9.
12. Pearson H, Stirling D. DNA extraction from tissue. Methods Mol Biol 2003;226:33-34.
13. Bieche I, Laurendeau I, Tozlu S, et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 1999;59:2759-2765.
14. Casas S, Nagy B, Elonen E, et al. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma 2003;44:1935-1941.
15. Wolff DJ, Bagg A, Cooley LD, et al. Guidance for fluorescence in situ hybridization testing in hemato-logic disorders. J Mol Diagn 2007;9:134-143.
16. Abu-Duhier FM, Goodeve AC, Care RS, et al. Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. Br J Haematol 2003;120:464-470.
17. Schuetz AN, Yin-Goen Q, Amin MB, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 2005;7:206-218.
18. Liu L, Qian J, Singh H, et al. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med 2007;131:1290-1297.
19. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-1603.
20. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003;33(Suppl):238-244.
21. Nackley AG, Shabalina SA, Tchivileva IE, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006;314:1930-1933.
22. Kluger HM, Dolled-Filhart M, Rodov S, et al. Macro-phage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004;10:173-177.
23. Goswami S, Sahai E, Wyckoff JB, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005;65:5278-5283.
24. Baiocchi G, Kavanagh JJ, Talpaz M, et al. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer 1991; 67:990-996.
25. Smith HO, Anderson PS, Kuo DY, et al. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin Cancer Res 1995;1:313-325.
26. Chambers SK, Kacinski BM, Ivins CM, et al. Over-expression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997;3:999-1007.
27. Toy EP, Chambers JT, Kacinski BM, et al. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;80:194-200.
28. Ide H, Seligson DB, Memarzadeh S, et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci USA 2002;99:14404-14409.
29. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-740.
30. Kirma N, Hammes LS, Liu YG, et al. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-beta1 in inducing c-fms expression. Cancer Res 2007;67: 1918-1926.
31. del Vecchio MT, Lazzi S, Bruni A, et al. DNA ploidy pattern in papillary renal cell carcinoma. Correlation with clinicopathological parameters and survival. Pathol Res Pract 1998;194:325-333.
32. Hamada I, Kato M, Yamasaki T, et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 2002;22: 4281-4284.
33. Douglass TG, Driggers L, Zhang JG, et al. Macrophage colony stimulating factor: not just for macrophages anymore! A gateway into complex biologies. Int Immunopharmacol 2008;8:1354-1376.
34. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
35. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
36. Grimaldi AM, Guida T, D'Attino R, et al. Sunitinib: bridging present and future cancer treatment. Ann Oncol 2007;18(Suppl 6):vi31-vi34.
37. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
38. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005;105: 3127-3132.
39. Dewar AL, Zannettino AC, Hughes TP, et al. Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle 2005;4:851-853.